Delving into the Latest Updates on Azilsartan Kamedoxomil/Chlorthalidone with Synapse

A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential Hypertension, Who Do Not Achieve Target Blood Pressure Following Treatment With TAK-491 40 mg Monotherapy

The purpose of this study is to evaluate the efficacy and safety of the fixed dose combinations of azilsartan medoxomil plus chlorthalidone (40/12.5 and 40/25 mg), once daily, in participants with grades 2 or 3 essential hypertension who do not reach target blood pressure following treatment with 40 mg azilsartan medoxomil monotherapy after 4 weeks.

Start Date01 Oct 2011

Sponsor / Collaborator

Takeda Pharmaceutical Co., Ltd.

NCT01309828

/ CompletedPhase 3

A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate Renal Impairment

The purpose of this study is to evaluate long term safety and tolerability of azilsartan medoxomil and chlorthalidone, once daily (QD), compared with olmesartan medoxomil and hydrochlorothiazide in hypertensive participants with moderate renal impairment.

Start Date01 Mar 2011

Sponsor / Collaborator

Takeda Pharmaceutical Co., Ltd.

NCT01033071

/ CompletedPhase 3

A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension

The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil plus chlorthalidone, once daily (QD), to olmesartan medoxomil plus hydrochlorothiazide in participants with moderate to severe hypertension.

Start Date01 Jan 2010

Sponsor / Collaborator

Takeda Pharmaceutical Co., Ltd.

100 Clinical Results associated with Azilsartan Kamedoxomil/Chlorthalidone

Login to view more data

100 Translational Medicine associated with Azilsartan Kamedoxomil/Chlorthalidone

Login to view more data

100 Patents (Medical) associated with Azilsartan Kamedoxomil/Chlorthalidone

Login to view more data

6

Literatures (Medical) associated with Azilsartan Kamedoxomil/Chlorthalidone

01 Jul 2020·Clinical TherapeuticsQ4 · MEDICINE

Single-pill Combination Therapy of Azilsartan Medoxomil/Chlorthalidone for Treatment of Hypertension: A Systematic Review

Q4 · MEDICINE

Review

Author: Kim, Gee-Hee ; Kwon, Ami

PURPOSEThe goal of this study was to review recent clinical studies of azilsartan medoxomil (AZL-M) and chlorthalidone (CLD), a combined angiotensin receptor blocker and thiazide-like diuretic, and its role in recently published guidelines. This review explores the role of AZL-M/CLD in treating patients with hypertension.METHODSA systematic review of literature published from 1990 to 2018 was performed by using the following key words: Edarbyclor, azilsartan, chlorthalidone, pharmacokinetic, and hypertension. Available English-language data from reviews, abstracts, presentations, and clinical trials regarding the use of AZL-M/CLD therapy specifically detailing effects of lowering blood pressure (BP) and outcomes on cardiovascular disease in humans and rats were reviewed.FINDINGSOne study compared a single-pill combination of AZL-M/CLD with co-administration of AZL-M and hydrochlorothiazide and found a greater reduction in clinic systolic BP with AZL-M/CLD (-35.1 mm Hg vs -29.5 mm Hg) than for AZL-M and hydrochlorothiazide. Another study of 153 patients with chronic kidney disease who received AZL-M/CLD or other single-pill combination agents found that AZL-M/CLD was more effective in lowering BP, achieving superior adherence. According to new guidelines, an increase in the prevalence of resistant hypertension can occur as a result of trying to lower target BP.IMPLICATIONSA powerful and effective medication that can increase patient compliance is essential to reduce the incidence of resistant hypertension. AZL-M/CLD is a powerful and safe antihypertensive medication that has been thoroughly studied in patients with hypertension.

01 Jan 2017·KardiologiiaQ4 · MEDICINE

Antihypertensive Efficacy of Fixed Combination Azilsartan Medoxomil / Chlorthalidone in Patients With Uncontrolled Arterial Hypertension

Q4 · MEDICINE

Article

Author: Kulakov, V V ; Villevalde, S V ; Kobalava, Z D

AIMTo study effects of a fixed azilsartan medoxomil/chlorthalidone combination (Edarbi Clo) on clinical, ambulatory and central blood pressure (BP) in patients with uncontrolled arterial hypertension (AH)).MATERIALS AND METHODSPatients (n=25) with uncontrolled AH were given fixed azilsartan medoxomil/chlorthalidone combination (40 / 12.5 mg / day) for 4 weeks. After 4 weeks, in patients who did not achieve target BP levels the dose was increased up to 40 / 25 mg / day. Duration of the study was 12 weeks.RESULTSAfter 12 weeks of treatment 88 % of patients achieved target clinical BP (.

01 Sep 2014·American Journal of Therapeutics

Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Renin–Angiotensin–Aldosterone System Antagonists

Review

Author: Aronow, Wilbert S ; Sankholkar, Kedar ; Lanier, Gregg

Health care providers managing hypertension (HTN) have a large selection of pharmacologic agents to choose from, including several different classes of drugs and many similar drugs within each class. Antagonism of the renin-angiotensin-aldosterone system has been shown to be very effective for HTN, especially in patients with cardiovascular disease, diabetes, and heart failure. Within this group, there have been 2 new agents recently introduced to the US market and approved by the Food and Drug Administration. It is important for the HTN specialist to be familiar with the merits of these 2 drugs: the angiotensin receptor blocker Edarbi (azilsartan) and the renin inhibitor Tekturna (aliskiren). Additionally, there have been several new, fixed-dose combination antihypertensives introduced to the market since 2006 that use a renin-angiotensin-aldosterone antagonist. Seven of these combine 2 drugs together in a single pill: Edarbyclor (azilsartan/chlorthalidone), Exforge (amlodipine/valsartan), Azor (olmesartan/amlodipine), Twynsta (amlodipine/telmisartan), Tekturna HCT [aliskiren/hydrochlorothiazide (HCTZ)], Valturna (aliskiren/valsartan), Tekamlo (aliskiren/amlodipine). Three triple-drug combination medications have also been introduced recently: Exforge HCT (amlodipine/valsartan/HCTZ), Tribenzor (olmesartan/amlodipine/HCTZ), and Amturnide (aliskiren/amlodipine/hydrocholorothiazide). This review will summarize the trial data and important pharmacologic merits of these 2 new renin-angiotensin-aldosterone antagonists and the advantages of initiating treatment with one of the new fixed-dose, combination drugs approved over the last 5 years.

1

News (Medical) associated with Azilsartan Kamedoxomil/Chlorthalidone

26 Jul 2017

·www.bioportfolio.com

Arbor Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

Summary Arbor Pharmaceuticals LLC Arbor is a healthcare products provider that develops prescription products for the hospital, cardiovascular and pediatric segments. The company offers licensing, manufacturing, development and commercialization of latestage prescription products. It also offers generic prescription and development stage products. Arbor's prescription products comprise edarbi, edarbyclor, bidil, nymalize, eryped, and erythromycin group of products. It offers products used in treatment areas including cardiovascular, emergency, pediatrics, psychiatry and endocrinology diseases. The company offers its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US. Arbor Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

Acquisition

100 Deals associated with Azilsartan Kamedoxomil/Chlorthalidone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	C09DA09	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypertension	BR	Takeda Pharmaceutical Co., Ltd.	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 3	US	The University of Chicago Medicine	01 Apr 2018
Chronic Kidney Diseases	Phase 3	US	Takeda Development Center Americas, Inc.	01 Apr 2018
Essential Hypertension	Discovery	AT	Takeda Pharmaceutical Co., Ltd.	01 Oct 2009
Essential Hypertension	Discovery	GB	Takeda Pharmaceutical Co., Ltd.	01 Oct 2009
Essential Hypertension	Discovery	DE	Takeda Pharmaceutical Co., Ltd.	01 Oct 2009
Essential Hypertension	Discovery	NL	Takeda Pharmaceutical Co., Ltd.	01 Oct 2009
Essential Hypertension	Discovery	PL	Takeda Pharmaceutical Co., Ltd.	01 Oct 2009
Hypertension	Discovery	IN	Synokem Pharmaceuticals Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01456169 (CTgov)	Phase 3	Essential Hypertension	507	Azilsartan medoxomil/placebo (Azilsartan Medoxomil 40 mg)	owivanwsib(rvzyqvaqbn) = tejozpllzt kdkyxmkvdf (azrcfxwfjg, ldlmlidkgi - qnddzxoxzi) View more	-	23 Apr 2014
				Azilsartan medoxomil - chlorthalidone (Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg)	owivanwsib(rvzyqvaqbn) = sevexvgzqz kdkyxmkvdf (azrcfxwfjg, tqiyyewnjl - fwptouvhgu) View more
NCT01309828 (CTgov)	Phase 3	Renal Insufficiency \| Hypertension	153	chlorthalidone (Azilsartan Medoxomil + Chlorthalidone)	(lnirfzdiqk) = smxmpcgksj rfsegpfsio (lvmgsfrify, zvlzidurpi - xcgjfwahwz) View more	-	13 Dec 2013
				hydrochlorothiazide+Olmesartan medoxomil (Olmesartan Medoxomil + Hydrochlorothiazide)	(lnirfzdiqk) = veezapebuz rfsegpfsio (lvmgsfrify, jojodowffl - tzfrnhbosb) View more
NCT00996281 (CTgov)	Phase 3	Essential Hypertension	837	chlorthalidone	cigmhweaew(mzcxwxqaic) = jlsfllnctt aceshrzcde (sqacscsvku, khzdgkaztf - lqafucukow) View more	-	12 Nov 2012
NCT00846365 (CTgov)	Phase 3	Essential Hypertension	1,085	chlorthalidone (Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD)	tztfrdylyg(jvjohuushf) = gtvhoatgae qvxlanjeiz (hdstmorkpd, taumsqxkig - ruoyzdcnox) View more	-	13 Mar 2012
				chlorthalidone (Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD)	tztfrdylyg(jvjohuushf) = ldqdjruitp qvxlanjeiz (hdstmorkpd, vxucxzmenh - dmhdmosgvo) View more
NCT01033071 (CTgov)	Phase 3	Essential Hypertension	1,071	chlorthalidone (Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD)	gdsmnodgdj(lqeqgxcmjj) = vhehaegfcy venhmgjccc (irgzcgasep, itnjederuq - abkiaxclyw) View more	-	07 Feb 2012
				chlorthalidone (Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD)	gdsmnodgdj(lqeqgxcmjj) = hqjvuzftsd venhmgjccc (irgzcgasep, losgczczmn - ubhsxyuwob) View more
NCT00818883 (CTgov)	Phase 3	Essential Hypertension	609	chlorthalidone (Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD)	uplosihpsu(aephaommwl) = kfecpskxhs fadjuquwmd (dabgcfyhfg, qjvtyiigvl - qgffdcodxw) View more	-	07 Feb 2012
				hydrochlorothiazide (Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD)	uplosihpsu(aephaommwl) = ydtfxinojo fadjuquwmd (dabgcfyhfg, uxfxnmcnqe - odrywlucks) View more
NCT00591773 (CTgov)	Phase 3	Essential Hypertension	551	chlorthalidone (Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD)	ztbtptvqze(nrkroekitx) = ldmnpktzyq gynhbybfcs (pkrbtcdyow, amwznryjfp - hehlttjevl) View more	-	19 Apr 2011
				chlorthalidone (Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD)	ztbtptvqze(nrkroekitx) = iupuiexbdp gynhbybfcs (pkrbtcdyow, epsmxxmxpp - gozalzfvoj) View more